Cero Therapeutics Regains Nasdaq Compliance After Bid Price Deficiency
South San Francisco, CA, July 8, 2025 – Cero Therapeutics Holdings, Inc. (NASDAQ: CERO), an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, announced on Monday that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The announcement follows a period of scrutiny after the company’s stock price fell below the $1.00 per share threshold required under Nasdaq Listing Rule 5550(a)(2).
On June 11, 2025, Cero received a notice from Nasdaq indicating that its common stock’s closing bid price had been below $1.00 for 30 consecutive business days, from April 25 to June 9, 2025, risking delisting. The company appealed the potential delisting by requesting a hearing before a Nasdaq Hearings Panel, which temporarily stayed the suspension of its securities. Nasdaq confirmed on July 7, 2025, that Cero had met the bid price requirement, canceling the scheduled hearing and ensuring continued listing on the Nasdaq Capital Market.
The compliance milestone follows Cero’s strategic financial and operational efforts. In June 2025, the company completed an additional closing of its Series D preferred stock sale, raising approximately $1.85 million through the issuance of 2,315 shares, bringing total proceeds from the private placement to over $2.6 million. Additionally, Cero executed a one-for-twenty reverse stock split on June 13, 2025, reducing its outstanding common shares to boost the per-share price, a move aimed at addressing Nasdaq’s requirements.
Cero also achieved a significant clinical milestone with the U.S. Food and Drug Administration granting Orphan Drug Designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML). This designation offers benefits like clinical trial design assistance and potential seven-year marketing exclusivity upon approval. The company is advancing CER-1236 in a Phase 1 clinical trial, with the first patient completing dose-limiting toxicity observation without issues, and plans to initiate a second trial for solid tumors later in 2025.
Despite these achievements, Cero faces ongoing challenges. Its stock, trading at $1.79 as of July 8, 2025, has declined over 98% in the past year, with a market capitalization of just $3.21 million. InvestingPro data highlights liquidity concerns, with a current ratio of 0.5 indicating short-term obligations exceed liquid assets.
CEO Chris Ehrlich emphasized the company’s focus on advancing its Chimeric Engulfment Receptor T cell (CER-T) platform, which integrates innate and adaptive immunity to target both hematological malignancies and solid tumors. “Regaining Nasdaq compliance allows us to concentrate on our mission to revolutionize cancer treatment,” Ehrlich stated.
The regained compliance marks a critical step for Cero, enabling it to maintain its public listing while pursuing its clinical and financial strategies. For further details, refer to Cero’s SEC filings at sec.gov or visit cero.bio.